NCT06710223View on ClinicalTrials.gov

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 3, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

SD-101

Toll-like receptor 9 (TLR9) agonist

DEVICE

Cryotherapy

Cryoablation of liver

DRUG

Tremelimumab

Anti-CTLA4

DRUG

Durvalumab

Anti-PDL1

Trial Locations (1)

92093

RECRUITING

University of California, San Diego, San Diego

All Listed Sponsors
collaborator

TriSalus Life Sciences, Inc.

INDUSTRY

lead

University of California, San Diego

OTHER